Progenics announces results from methylnaltrexone Phase II clinical trial in opioid-induced constipation.

(From Chemical Business NewsBase - Press Release)

Progenics Pharmaceuticals Inc announced top-line results from a Phase II clinical trial of its investigational drug, methylnaltrexone, for the treatment of opioid-induced constipation. In Dec 2002, the company reported preliminary results from the open-label portion of this clinical study. Analysis of the randomized double-blind results show that the study met its objectives, and that the drug continued to show evidence that it was well tolerated. The results confirm and extend the findings from the previously reported open-label portion of the study and support the dosing regimen selected for the ongoing Phase III …